https://pathiostherapeutics.com/news/ 2026-07-08T09:26:59+00:00 https://pathiostherapeutics.com/pathios-therapeutics-to-present-preclinical-data-highlighting-potential-of-gpr65-inhibition-as-a-powerful-anti-tumour-immunotherapy-strategy-at-sitc-2022/ 2023-10-26T14:20:51+00:00 https://pathiostherapeutics.com/wp-content/uploads/2022/11/11.jpg https://pathiostherapeutics.com/pathios-therapeutics-highlights-role-of-gpr65-as-critical-innate-immune-checkpoint-in-the-human-tumor-microenvironment-and-reports-anti-tumor-activity-of-gpr65-inhibition-during-podium-presentation-at/ 2023-10-26T14:21:42+00:00 https://pathiostherapeutics.com/wp-content/uploads/2022/11/9.jpg https://pathiostherapeutics.com/pathios-therapeutics-presents-preclinical-in-vivo-proof-of-concept-data-for-small-molecule-gpr65-inhibitor-in-human-pdx-cancer-model/ 2023-10-26T14:22:11+00:00 https://pathiostherapeutics.com/wp-content/uploads/2022/11/10.jpg https://pathiostherapeutics.com/pathios-therapeutics-boosted-by-award-of-significant-innovate-uk-funding/ 2023-10-26T14:23:20+00:00 https://pathiostherapeutics.com/wp-content/uploads/2021/03/Untitled-design-22.jpg https://pathiostherapeutics.com/endpoints-news-reports-canaan-backs-pathios-search-for-small-molecule-drugs-that-hit-orphan-gpcr/ 2023-11-06T14:55:25+00:00 https://pathiostherapeutics.com/wp-content/uploads/2019/12/15.jpg https://pathiostherapeutics.com/partnership-forms-for-first-in-class-therapies-for-autoimmune-diseases-and-immuno-oncology/ 2023-11-06T15:01:40+00:00 https://pathiostherapeutics.com/wp-content/uploads/2019/12/13.jpg https://pathiostherapeutics.com/wp-content/uploads/2019/07/biopharm-logo.jpg https://pathiostherapeutics.com/sygnature-backs-pathios-in-hunt-for-gpr65-modulators/ 2023-11-06T15:03:03+00:00 https://pathiostherapeutics.com/wp-content/uploads/2019/12/16.jpg https://pathiostherapeutics.com/wp-content/uploads/2019/07/fiercebiotech-logo.png https://pathiostherapeutics.com/pathios-therapeutics-and-sygnature-discovery-sign-a-strategic-and-innovative-partnership-to-develop-first-in-class-therapies-in-autoimmune-disease-and-immuno-oncology/ 2023-11-06T15:32:30+00:00 https://pathiostherapeutics.com/wp-content/uploads/2019/02/8.8m.jpg https://pathiostherapeutics.com/seriesapressrelease/ 2023-11-08T23:07:58+00:00 https://pathiostherapeutics.com/wp-content/uploads/2019/12/14-1.jpg https://pathiostherapeutics.com/pathios-announces-appointment-of-dr-tobias-bopp-as-the-foundational-member-of-its-sab/ 2023-11-17T23:21:33+00:00 https://pathiostherapeutics.com/wp-content/uploads/2019/12/8.jpg https://pathiostherapeutics.com/wp-content/uploads/2020/02/Tobias.jpg https://pathiostherapeutics.com/paul-higham-ceo-clinic/ 2024-09-05T12:08:30+00:00 https://pathiostherapeutics.com/wp-content/uploads/2024/07/Website-stock-images.png https://pathiostherapeutics.com/pathios-therapeutics-announces-dosing-of-first-patient-in-phase-1-2-clinical-study-of-gpr65-inhibitor-ptt-4256-in-patients-with-advanced-solid-cancers/ 2024-11-20T12:00:02+00:00 https://pathiostherapeutics.com/wp-content/uploads/2024/11/Light-9.png https://pathiostherapeutics.com/pathios-series-b-bms/ 2024-11-20T08:27:27+00:00 https://pathiostherapeutics.com/wp-content/uploads/2024/04/Screenshot-2024-04-16-at-20.04.24.png https://pathiostherapeutics.com/innovate-uk-grant/ 2024-11-20T08:28:22+00:00 https://pathiostherapeutics.com/wp-content/uploads/2023/09/5.jpg https://pathiostherapeutics.com/pathios-therapeutics-unveils-ptt-4256-a-highly-potent-and-selective-inhibitor-of-gpr65-in-presentation-at-american-association-for-cancer-research-aacr-annual-meeting-2023/ 2024-11-20T08:28:59+00:00 https://pathiostherapeutics.com/wp-content/uploads/2023/04/Pathios-poster.jpg https://pathiostherapeutics.com/pathios-therapeutics-appoints-jeanmarie-guenot-ph-d-as-non-executive-director/ 2024-11-20T08:30:01+00:00 https://pathiostherapeutics.com/wp-content/uploads/2022/11/7.jpg https://pathiostherapeutics.com/wp-content/uploads/2023/10/Jeanmarie.jpg https://pathiostherapeutics.com/pathios-therapeutics-appoints-sumeet-ambarkhane-m-d-as-chief-medical-officer/ 2025-09-24T08:53:46+00:00 https://pathiostherapeutics.com/wp-content/uploads/2025/03/Gradient-3.jpg https://pathiostherapeutics.com/pathios-therapeutics-appoints-jon-wigginton-m-d-as-non-executive-director/ 2025-09-24T11:00:23+00:00 https://pathiostherapeutics.com/wp-content/uploads/2025/09/PR-Header.jpg https://pathiostherapeutics.com/pathios-therapeutics-unveils-first-public-clinical-data-for-first-in-class-gpr65-antagonist-ptt-4256-at-sitc-2025/ 2026-07-08T09:25:58+00:00 https://pathiostherapeutics.com/wp-content/uploads/2026/04/Cancers_Publication_cover.jpg https://pathiostherapeutics.com/pathios-published-in-cancers-2026-a-novel-approach-in-renal-cell-carcinoma/ 2026-07-08T09:26:24+00:00 https://pathiostherapeutics.com/wp-content/uploads/2025/03/Gradient-3.jpg https://pathiostherapeutics.com/pathios-therapeutics-announced-promising-clinical-progress-for-first-in-class-gpr65-antagonist-ptt-4256-at-asco-2026/ 2026-07-08T09:26:59+00:00 https://pathiostherapeutics.com/wp-content/uploads/2025/03/Gradient-5.jpg